United States securities and exchange commission logo





                             February 7, 2022

       Yulin Wang
       Chief Executive Officer
       Meihua International Medical Technologies Co., Ltd.
       88 Tongda Road, Touqiao Town
       Guangling District, Yangzhou, 225000
       People   s Republic of China

                                                        Re: Meihua
International Medical Technologies Co., Ltd.
                                                            Amendment No. 8 to
                                                            Registration
Statement on Form F-1
                                                            Filed February 3,
2022
                                                            File No. 333-258659

       Dear Mr. Wang:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 8 to Form F-1

       Capitalization, page 52

   1.                                                   Please revise your
presentation to include indebtness, such as short-term bank
                                                        borrowings, as part of
your capitalization table.
   2.                                                   Please expand the
disclosures for the pro forma column that includes the underwriter's
                                                        exercise of the
overallotment option in full to disclose your basis for assuming the
                                                        underwriters will
exercise the option in full. Please also address this comment for your
                                                        dilution presentation.
 Yulin Wang
FirstName LastNameYulin    Wang
Meihua International Medical Technologies Co., Ltd.
Comapany7,NameMeihua
February   2022         International Medical Technologies Co., Ltd.
February
Page 2 7, 2022 Page 2
FirstName LastName
Dilution, page 54

3.       Please expand the initial sentence to disclose the dollar amount of
net tangible book value
         in addition to the per ordinary share value.
       You may contact Tracey Houser at 202-551-3736 or Brian Cascio at
202-551-3676 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Celeste Murphy at 202-551-3257 with any
other questions.



                                                              Sincerely,

                                                              Division of
Corporation Finance
                                                              Office of Life
Sciences
cc:      Joe Laxague, Esq.